1. Kryptopyrrole (2,4-dimethyl-3-ethyl pyrrole) was shown to elevate the urinary porphyrin excretion and the hepatic content of porphyrins in the rat. The simultaneous administration of 8-aminolaevuiinic acid increased these effects.
Introduction
In 1961, Irvine described a substance ('mauve factor') from the urine of psychiatric patients which reacted with Ehrlich's reagent to produce a mauve colour. This factor, identified as 2,4-dimethyl-3-ethyl pyrrole (kryptopyrrole) (Irvine, Bayne, Miyashita & Majer, 1969; Sohler, Beck & Noval, 1970) , has been shown to be present in the urine of 30-60% of psychotic subjects (Sohler, Renz, Smith & Kaufman, 1967) . Husak, Durko & Karsai (1972) have reported the excretion of kryptopyrrole in patients with acute intermittent porphyria and porphyria cutanea tarda, and in a proportion of patients with acute schizophrenia who also excreted excess of porphyrins. The biological origin of kryptopyrrole, although at present unknown, is not artifactual (Sohler et 
1970
) and, as yet, its quantification in urine has been frustrated by its extreme lability.
Recently Berek, Husak & Durko (1975) have shown that synthetic kryptopyrrole raises porphyrin production in bacterial cultures. The following work was designed to study the effect of kryptopyrrole on porphyrin synthesis in the rat. In addition, urinary kryptopyrrole excretion has been studied in acute intermittent porphyria and for the first time in patients with hereditary coproporphyria and variegate porphyria.
Materials and methods

Animal studies
Four groups of six male Sprague-Dawley rats of 250 g weight were used. All groups were injected daily with solutions as follows: group 1, 0.2 ml of propylene glycol and 0.5 ml of sodium chloride (150 mmol/l; saline); group 2, 160 pmol of kryptopyrrole (Aldrich) in 0.2 ml of propylene glycol and 0.5 ml of saline; group 3, 0.2 ml of propylene glycol and 0.1 19 pmol of 8-aminolaevulinic acid in 03 ml of saline; group 4, 160 pmol of kryptopyrrole in 0.2 ml of propylene glycol and 0.1 19 pmol of S-aminolaevulinic acid in 0.5 ml of saline. Solutions were adjusted to p 7H with sodium bicarbonate (1 mol/l). The rats were housed in metabolic cages in groups of six and given food and water adlibitum. A base-line 24 h urine collection was made for each group before injection. Twenty-four hour urine volumes were then collected for 4 days after the first injection. On the fifth day, the animals were killed by cervical dislocation and exsanguination and their livers removed for porphy-rin estimation. Urinary uroporphyrin and coproporphyrin and hepatic coproporphyrin and protoporphyrin were measured by the method of Rimington (1971) and urinary &aminolaevulinic acid and porphobilinogen by the method of Mauzerall & Granick (1956) .
Patient studies
A group of seventeen patients with three forms of hereditary hepatic porphyria was studied-acute intermittent porphyria (AIP), hereditary coproporphyria (HC) and variegate porphyria (VP). Patients with the biochemical abnormalities of porphyria who have never had an acute attack, have been termed latent porphyrics. These cases were diagnosed by routine porphyrin screening of first-degree relatives of patients known to have the condition.
The urine samples of four patients with porphyria in attack (two AIP, one VP, one HC), of four patients in remission (three AIP, one HC) and of nine latent porphyrics (one AIP, six HC, two VP) were examined. Ten normal subjects were also screened.
Urinary kryptopyrrole excretion was detected by a variation of the method of Irvine (1961) . This gives a qualitative measure of the presence of kryptopyrrole in urine, allowing for the detection of kryptopyrrole in urine at concentrations greater than 30 nmol/l.
Fresh urine (100 ml) was mixed with 2 g of activated charcoal (BDH Ltd), allowed to stand for 2 h and then filtered in a Buchner funnel. After the charcoal was washed with 80 ml of distilled water the kryptopyrrole was eluted with 100 ml of acetone, which was evaporated in vacuo at 30°C. The residue was taken up in water and extracted three times with 3.5 ml of peroxide-free diethyl ether. Acetone (2.2 ml) was then added and the mixture extracted twice with 6.6 ml of ether. Both ether fractions were flashevaporated at 30°C, the residue being dissolved in 2 ml of acetone and then applied to Whatman 3 MM chromatography paper. A standard of synthetic kryptopyrrole (400 nmol) was applied at the same time and ascending chromatography run for 12 h in the solvent system propan-2-ol/water/ammonia soh. (sp. gr. 0.88) (20:2:1). The chromatograms were dried in cool air and the krytopyrrole was visualized as a purple-blue spot (RF value 0.9) by development in Ehrlich's reagent (1 g of 4-dimethylaminobenzaldehyde dissolved in hydrochloric acidlmethanol, 1 :9, vlv) followed by heating at 55°C. Urinary porphyrins and porphyrin precursors were measured as above. Faecal porphyrins were measured by the method of Rimington (1971) .
Results
Rats
Treatment of rats with kryptopyrrole alone was found to elevate urinary excretion of coproporphyrin and uroporphyrin (Table 1) whereas treatment with ALA'l) alone increased the urinary excretion of coproporphyrin and uroporphyrin and also that of the porphyrin precursors ALA and porphobilinogen.
In animals treated with ALA and kryptopyrrole, the increase in porphyrin excretion was greater than the combined increases when ALA and krytopyrrole were given separately. Porphyrin precursor excretion was markedly greater than in rats treated with ALA.
Hepatic coproporphyrin and protoporphyrin concentrations were increased in all three groups with the greatest significance being found in those treated with both kryptopyrrole and ALA.
Patients
In all the patients with porphyria, in attack or remission, it was possible to demonstrate kryptopyrrole in the urine. In all patients with latent porphyria and in ten normal subjects no urinary kryptopyrrole could be detected.
Discussion
The present results demonstrate that kryptopyrrole or one of its metabolites is porphyrinogenic in the rat. This effect is heightened by simultaneous administration of ALA, a situation analogous to that found in the acute porphyric attack, where concentrations of circulating ALA are raised by increased ALA synthase activity.
Kryptopyrrole has been consistently found in the urine of a proportion of psychotic patients. Husak et al. (1972, 1973) have shown that in acute schizophrenia with increased urinary porphyrin and precursor excretion, urinary kryptopyrrole could not always be detected. Urinary kryptopyrrole has been shown to occur in patients with acute intermittent porphyria, hereditary coproporphyria and variegate porphyria either in attack or remission. KryptoAbbreviation : ALA, 6-aminolaevulinic-acid. Irvine (1974) has postdated that the substance found in urine may not be kryptopyrrole but an oxidized form, namely 5-hydroxykryptopyrrole lactam (4-ethyl-5-hydroxy-3,s-dimethyl-A3-pyrrolin-2-one). This metabolite has been shown to be the sole product of the action of a rat microsomal oxygenase on kryptopyrrole (D. G. Irvine, personal communication) . The present study does not exclude the possibility that the porphyrinogenic compound is this lactam rather than kryptopyrrole itself.
The exact relationship between psychosis, porphyria and kryptopyrrole and/or its metabolite is at present unknown but it is tempting to offer it as an aetiological link between psychosis and hereditary hepatic porphyria in which a psychotic illness often plays a part. Evidence for this is, at present, lacking.
Kryptopyrrole or its lactam may be purely a product of abnormal porphyrin metabolism but these results suggest it may play a role in the derangement of porphyrin metabolism. Its absence in the urine of latent porphyrics would suggest that it may be associated with the subtle changes which transform latency to activity.
